Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Generic entry, reformulations and promotion of SSRIs in the US.

Huskamp HA, Donohue JM, Koss C, Berndt ER, Frank RG.

Pharmacoeconomics. 2008;26(7):603-16.

2.

Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression.

Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG.

Med Care. 2004 Dec;42(12):1176-85.

PMID:
15550797
3.

Recent trends in brand-name and generic drug competition.

Grabowski H, Long G, Mortimer R.

J Med Econ. 2014 Mar;17(3):207-14. doi: 10.3111/13696998.2013.873723. Epub 2013 Dec 23.

PMID:
24320785
4.

Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.

Hong SH, Shepherd MD, Scoones D, Wan TT.

J Manag Care Pharm. 2005 Nov-Dec;11(9):746-54.

5.

An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.

Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.

J Ment Health Policy Econ. 2002 Mar;5(1):3-19.

PMID:
12529566
6.
7.

A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998.

Ma J, Stafford RS, Cockburn IM, Finkelstein SN.

Clin Ther. 2003 May;25(5):1503-17.

PMID:
12867225
9.

The impact of manufacturer coupon use in the statin market.

Daugherty JB, Maciejewski ML, Farley JF.

J Manag Care Pharm. 2013 Nov-Dec;19(9):765-72.

10.

Private expenditures on brand name prescription drugs after generic entry.

Balaban DY, Dhalla IA, Law MR, Bell CM.

Appl Health Econ Health Policy. 2013 Oct;11(5):523-9. doi: 10.1007/s40258-013-0052-y.

PMID:
23979876
11.

The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

Kesselheim AS, Avorn J, Sarpatwari A.

JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237. Review.

PMID:
27552619
12.

Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative.

Majumdar SR, Almasi EA, Stafford RS.

JAMA. 2004 Oct 27;292(16):1983-8.

PMID:
15507584
13.

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.

Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.

Ann Pharmacother. 2011 Apr;45(4):441-51. doi: 10.1345/aph.1P482. Epub 2011 Mar 17.

PMID:
21415162
14.
15.

Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.

Panzer PE, Regan TS, Chiao E, Sarnes MW.

Am J Manag Care. 2005 Oct;11(12 Suppl):S370-9.

16.

A decade of direct-to-consumer advertising of prescription drugs.

Donohue JM, Cevasco M, Rosenthal MB.

N Engl J Med. 2007 Aug 16;357(7):673-81.

17.

Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence.

Datta A, Dave D.

Health Econ. 2017 Apr;26(4):450-468. doi: 10.1002/hec.3323. Epub 2016 Feb 19.

PMID:
26893065
18.

Effects of promotion on pharmaceutical demand.

Mackowiak JI, Gagnon JP.

Soc Sci Med. 1985;20(11):1191-7.

PMID:
4023756
19.

Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.

Kim H.

Int J Health Policy Manag. 2015 Aug 25;4(12):813-21. doi: 10.15171/ijhpm.2015.157.

20.

Employer drug benefit plans and spending on prescription drugs.

Joyce GF, Escarce JJ, Solomon MD, Goldman DP.

JAMA. 2002 Oct 9;288(14):1733-9. Erratum in: JAMA 2002 Nov 20;288(19):2409.

PMID:
12365957

Supplemental Content

Support Center